Review of the Omnipod® 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes.
Ther Deliv, 2020/08;11(8):507-519.
Cobry EC[1], Berget C[1], Messer LH[1], Forlenza GP[1]
Affiliations
PMID: 32723002DOI: 10.4155/tde-2020-0055
Abstract
Type 1 diabetes (T1D) is a medical condition that requires constant management, including monitoring of blood glucose levels and administration of insulin. Advancements in diabetes technology have offered methods to reduce the burden on people with T1D. Several hybrid closed-loop systems are commercially available or in clinical trials, each with unique features to improve care for patients with T1D. This article reviews the Omnipod® 5 Automated Glucose Control System Powered by Horizon™ and the safety and efficacy data to support its use in the management of T1D.
Keywords: AP; CGM; HCL; Omnipod® 5 System; T1D; artificial pancreas; automated insulin delivery; insulin pump
MeSH terms
Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems
More resources
Full text:
Europe PubMed Central; PubMed Central
EndNote: Download